Anti-NGF painkillers back on track?

  title={Anti-NGF painkillers back on track?},
  author={David Holmes},
  journal={Nature Reviews Drug Discovery},
The history of therapeutics that target nerve growth factor (NGF) has been nothing if not eventful. At the beginning of 2010, expectations were high that anti-NGF drugs would emerge as the first new class of broadly applicable painkillers in decades, with several agents in clinical trials. By the end of the year, however, safety concerns led the US Food and Drug Administration (FDA) to put most of these trials on hold. The story took another eagerly anticipated twist in March this year, when… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS